Raul Tonda

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1385923/publications.pdf

Version: 2024-02-01

40 1,036 17 papers citations h-index

42 42 42 2128 all docs docs citations times ranked citing authors

30

g-index

#	Article	IF	Citations
1	The RDâ€Connect Genomeâ€Phenome Analysis Platform: Accelerating diagnosis, research, and gene discovery for rare diseases. Human Mutation, 2022, , .	2.5	18
2	PrecisionFDA Truth Challenge V2: Calling variants from short and long reads in difficult-to-map regions. Cell Genomics, 2022, 2, 100129.	6.5	72
3	The Genetic Landscape of Inherited Retinal Diseases in a Mexican Cohort: Genes, Mutations and Phenotypes. Genes, 2021, 12, 1824.	2.4	15
4	Diagnostic value of bone marrow core biopsy patterns in lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia and description of its mutational profiles by targeted NGS. Journal of Clinical Pathology, 2020, 73, 571-577.	2.0	7
5	A de novo heterozygous missense BSCL2 variant in 2 siblings with intractable developmental and epileptic encephalopathy. Seizure: the Journal of the British Epilepsy Association, 2019, 71, 161-165.	2.0	8
6	Chromosome 12p Amplification in Triple-Negative/ <i>BRCA1-</i> li>Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity. Cancer Research, 2019, 79, 4258-4270.	0.9	17
7	A De Novo FOXP1 Truncating Mutation in a Patient Originally Diagnosed as C Syndrome. Scientific Reports, 2018, 8, 694.	3.3	11
8	Novel mutation in the choroideremia gene and multi-Mendelian phenotypes in Spanish families. British Journal of Ophthalmology, 2018, 102, 1378-1386.	3.9	7
9	Heterozygous <i>STUB1</i> mutation causes familial ataxia with cognitive affective syndrome (SCA48). Neurology, 2018, 91, e1988-e1998.	1.1	81
10	Deep analysis of acquired resistance to FGFR1 inhibitor identifies MET and AKT activation and an expansion of AKT1 mutant cells. Oncotarget, 2018, 9, 31549-31558.	1.8	8
11	Whole-Exome Sequencing of Congenital Glaucoma Patients Reveals Hypermorphic Variants in GPATCH3, a New Gene Involved in Ocular and Craniofacial Development. Scientific Reports, 2017, 7, 46175.	3.3	22
12	Benchmarking of Whole Exome Sequencing and Ad Hoc Designed Panels for Genetic Testing of Hereditary Cancer. Scientific Reports, 2017, 7, 37984.	3.3	35
13	ATRX driver mutation in a composite malignant pheochromocytoma. Cancer Genetics, 2016, 209, 272-277.	0.4	24
14	Novel Candidate Genes and a Wide Spectrum of Structural and Point Mutations Responsible for Inherited Retinal Dystrophies Revealed by Exome Sequencing. PLoS ONE, 2016, 11, e0168966.	2.5	40
15	Runs of homozygosity reveal signatures of positive selection for reproduction traits in breed and non-breed horses. BMC Genomics, 2015, 16, 764.	2.8	125
16	Combined Genetic and High-Throughput Strategies for Molecular Diagnosis of Inherited Retinal Dystrophies. PLoS ONE, 2014, 9, e88410.	2.5	32
17	Next generation sequencing gives an insight into the characteristics of highly selected breeds versus non-breed horses in the course of domestication. BMC Genomics, 2014, 15, 562.	2.8	24
18	An In-Depth Characterization of the Major Psoriasis Susceptibility Locus Identifies Candidate Susceptibility Alleles within an HLA-C Enhancer Element. PLoS ONE, 2013, 8, e71690.	2.5	45

#	Article	IF	CITATIONS
19	Relative contributions of collagen and tissue factor to thrombus formation on damaged vascular vessels: in-vitro studies with circulating blood. Coronary Artery Disease, 2009, 20, 392-399.	0.7	5
20	Haemodialysis through a cellulose membrane induces dephosphorylation of CD11b and promotes leukocyte adhesion to endothelial cells. Clinical and Investigative Medicine, 2009, 32, 48.	0.6	2
21	Platelets interact with tissue factor immobilized on surfaces: effects of shear rate. European Journal of Clinical Investigation, 2008, 38, 34-42.	3.4	6
22	Effects on primary haemostasis of an anti-inflammatory agent with 5-lipoxygenase and cyclooxygenase inhibitory activity. Journal of Cardiovascular Medicine, 2006, 7, 859-865.	1.5	3
23	Role of Tissue Factor in Platelet Adhesion: Real-Time Perfusion Studies Blood, 2006, 108, 1794-1794.	1.4	0
24	Tissue Factor Firmly Immobilized on Surfaces Promotes Platelet Adhesion and Fibrin Formation in Studies with Circulating Human Blood: Importance of Shear Rate Conditions and FVIIa Blood, 2006, 108, 3925-3925.	1.4	0
25	Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Transfusion, 2005, 45, 911-919.	1.6	108
26	Antithrombotic effect of a new nitric oxide donor (LA419) on experimental thrombogenesis. European Journal of Clinical Investigation, 2005, 35, 337-342.	3.4	8
27	In vitro evaluation of platelet reactivity toward annuloplasty devices treated with heparin coating: Studies under flow conditions. Journal of Biomedical Materials Research - Part A, 2005, 75A, 192-198.	4.0	4
28	Efficient tyrosine phosphorylation of proteins after activation of platelets with thrombin depends on intact glycoprotein lb. Platelets, 2005, 16, 453-461.	2.3	5
29	Effect of P-Selectin on Phosphatidylserine Exposure and Surface-Dependent Thrombin Generation on Monocytes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1065-1070.	2.4	77
30	Recombinant Activated FVII (rFVIIa) Corrects Platelet Dysfunction in Hemophilic Patients: Study on Collagen and Tissue Factor Surfaces at High Shear Rates Blood, 2005, 106, 4034-4034.	1.4	18
31	Biocompatibility of Cellulosic and Synthetic Membranes Assessed by Leukocyte Activation. American Journal of Nephrology, 2004, 24, 235-241.	3.1	24
32	Evaluation of effects of rofecoxib on platelet function in an in vitro model of thrombosis with circulating human blood. European Journal of Clinical Investigation, 2004, 34, 297-302.	3.4	20
33	Hemostatic effect of activated recombinant factor VIIa in Bernard-Soulier syndrome: studies in an in vitro model. Transfusion, 2004, 44, 1790-1791.	1.6	6
34	Platelet membrane fragments enhance the procoagulant effect of recombinant factor VIIa in studies with circulating human blood under conditions of experimental thrombocytopenia. Seminars in Hematology, 2004, 41, 157-162.	3.4	12
35	Direct Activation of Platelets by Tissue Factor Is Amplified by FVIIa and Potentiated by Serotonin: Influence of Shear Rate Blood, 2004, 104, 3906-3906.	1.4	0
36	Increased local procoagulant action: a mechanism contributing to the favorable hemostatic effect of recombinant FVIIa in PLT disorders. Transfusion, 2003, 43, 885-892.	1.6	47

RAUL TONDA

#	Article	IF	CITATION
37	Atomic Force Microscopy of Liposomes Bearing Fibrinogen. Bioconjugate Chemistry, 2003, 14, 593-600.	3.6	20
38	Hemostatic effect of activated recombinant factor VII (rFVIIa) in liver disease: studies in an in vitro model. Journal of Hepatology, 2003, 39, 954-959.	3.7	22
39	Recombinant factor VIIa (NovoSeven $\hat{A}^{@}$) restores deficient coagulation: Experience from an ex vivo model. Seminars in Hematology, 2001, 38, 10-14.	3.4	16
40	Recombinant factor VIIa (Novoseven[reg]) restores deficient coagulation: Experience from an ex vivo model. Seminars in Hematology, 2001, 38, 10-14.	3.4	5